Sound Bioventures expands portfolio with new investment in US company NephroDI Therapeutics to accelerate development of NDI-5001 for pediatric orphan kidney disease New funding will accelerate NephroDI’s asset, NDI-5001, into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI)New investment complements NephroDI’s previously...

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford  New funding enables Theolytics...

Sound Bioventures appoints Fredrik Lehmann as its first Entrepreneur-in-Residence Stockholm, Sweden and Cambridge, MA, USA – 13 October 2023 - Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA...